Introduction
Corcept Therapeutics (CORT) is a small-cap ($1.43B) commercial-stage biopharmaceutical company developing innovative therapies for the treatment of oncologic, metabolic and endocrine diseases as well as psychiatric disorders.
Its singular commercialized product, Korlym (mifepristone), is a once-daily oral therapeutics for hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance.
Relacorilant (formerly CORT125134) is glucocorticoid receptor antagonist in Phase 3 and Phase 2 clinical trials for Cushing syndrome and pancreatic cancer, respectively. Topline data for Cushing syndrome is expected by early Q2/2021.